- My News
- All News
- Most Popular
The new leadership additions follow the completion of a successful randomized control trial of its product which has clinically proven to be three times more effective in reversing autoimmune symptoms than medical intervention alone.
Health systems throughout the world are under incredible cost pressure, and digital medicine and digital therapeutics are perfectly placed to meet the task of increasing quality of care while reducing costs to handle a population's health. The Mymee Remission Protocol™ is aimed to reduce healthcare expenditures for insurance companies and employer health plans.
"Bringing together a team of seasoned executives experienced in data and healthcare will further position Mymee to enable the future of intervention intelligence, creating the most effective autoimmunity treatment," says Mette Dyhrberg, Founder and CEO of Mymee, Inc. "Marie, Nicole, Robyn and Mara have great experiences that will complement the other strong members of our team well."
Mymee's focus on clinical validation and the expansion in the executive team is a deliberate effort to operationalize significant commercial opportunities based on positive clinical results. In her role as Vice President of Marketing, Robyn Bollhorst will take the Mymee product to market by driving the execution of the company's growth marketing, brand strategy and communications. As the company's General Counsel, Mara Babin will provide structure and management to the company's intellectual property. In her capacity as Chief Medical Officer, Dr. Nicole Bundy will further enhance the protocol and drive strategic regulatory product needs. Leading the firm's operations as the Chief Operating Officer, Marie Klok Crump will oversee long-term strategic planning for development and scaling of the company's infrastructure needed to support growth and commercialization.
The Mymee Story
Mymee is a digital therapeutics company with a comprehensive platform that enables personalized diagnosis of autoimmune disease triggers, delivers prescriptive therapeutic interventions, and measures clinically meaningful benefits for patients. The company was founded by Mette Dyhrberg, a serial entrepreneur from Denmark, who first entered the functional medicine arena in an attempt to tackle her own serious autoimmune disease: She had suffered from 6 different autoimmune conditions, and traditional medicine had failed to provide a solution: She had become an untreatable "n of 1."
Through Mette's expansive process of research, personal diagnosis, experimentation, and her ultimate success in reversing her own autoimmune disease, she gained deep understanding that was nowhere to be found in published literature or standard of care. Mette's passion to help others and find solutions to unsolvable complex problems, and her experience building companies, led her to form Mymee to tackle the challenge of how to build a scalable personalized diagnostic and treatment platform for autoimmune diseases. Her objective: Help patients to accomplish what she had been able to do for herself.
Drawing on ideas and methods from lean, systems thinking and software engineering, the Mymee platform was built with the flexibility to support individual patients across a variety of autoimmune conditions.
For more information, visit https://www.mymee.com.
SOURCE Mymee, Inc.
Did you like this article?